We are proud to announce the investment of over €2.5million into innovative prostate cancer research in Ireland, made possible by the hard work and dedication of our Mo Bros and Mo Sistas, and the unrivalled generosity of our donors.

We are proud to announce the investment of over €2.5million into innovative prostate cancer research in Ireland, made possible by the hard work and dedication of our Mo Bros and Mo Sistas, and the unrivalled generosity of our donors. In partnership with our men’s health partner the Irish Cancer Society, this grant has been awarded to one multi-disciplinary team working across three innovative prostate cancer research projects centred on a common theme.
 
The grant, worth  €750,000 over two years, as been award to the Irish Programme for Stratified Prostate Cancer Therapy (iPROSPECT) led by Consultant Medical Oncologist, Dr Ray McDermott. This iPROSPECT programme consists of three connected projects, designed to bring about a transformation from current practice to a more individual and personalised treatment of patients with metastatic prostate cancer in order to improve patient outcomes.
 
Project 1

• Title: Impact on tumour response to metastatic targeted therapies
• Project Lead: Dr Sharon Anneve Glynn – National University of Ireland Galway

 
Project 2

• Title: Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy
• Project Lead: Professor Stephen Finn – St. James Hospital and Trinity College Dublin

 
Project 3

• Title: Evolution of the CRPC Epigenome and its Clinical Application for delivering Precision Medicine
• Project Lead: Dr Antoinette Perry – Trinity College Dublin

 
In addition to this investment, €350,000 was also awarded to Molecular Medicine Ireland. Led by Consultant Urologist, Dr David Galvin, Chairperson and Clinical Lead, Prostate Cancer Committee, National Cancer Control Programme (NCCP), this investment will help establish the first Irish Prostate Cancer Outcomes Research (IPCOR) in Ireland that will monitor, benchmark and publicly report annually on outcomes of prostate cancer treatment and care.
 
Head of Research at the Irish Cancer Society, Professor John Fitzpatrick said, “Today’s announcement is an exciting opportunity for the prostate cancer research community in Ireland to come together and collaborate to understand the challenges of prostate cancer and to take a fresh, innovative approach to transforming our knowledge of this disease and, through IPCOR, to publicly report on outcomes of treatment and care in this country.”

See more of what we fund